The NHS spending watchdog said said the cost-effectiveness estimates of trastuzumab deruxtecan were too high for it to be recommended for use in the health service.
patients in England with a certain form of the disease could be “denied” access to a new treatment after health officials provisionally rejected a drug for NHS use, a charity has said.trastuzumab deruxtecanWhile the NHS spending watchdog said the treatment is a “potentially significant development” for patients with this type of cancer, there were uncertainties in the information provided by manufacturer Daiichi Sankyo.
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said: “Today’s devastating provisional decision will deny certain patients living with incurable secondary breast cancer of the hope that trastuzumab deruxtecan could bring them, of both more time to live and more time before their disease progresses.
Helen Crawford, patient advocate from METUPUK, a patient group dedicated to metastatic breast cancer, added: “We have been given this hope for so long that HER2-low treatments for metastatic breast cancer were in development and coming. I work, I’m a parent and I contribute to society. Why shouldn’t I and thenot be worth the cost for the new drug?
There is now a period of consultation about the provisional recommendation until 5pm on 17 October. The Nice Committee will then reconsider this treatment at a committee meeting on 7 November.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Number of appointments rescheduled after NHS strike action passes one million, new figures showThe data comes as consultants and junior doctors took joint strike action for the first time in NHS history last week.
Lire la suite »
New breast cancer treatment not approved for NHS useThe health spending watchdog said the ‘the cost-effectiveness estimates were too high for it to be recommended for use in the NHS’.
Lire la suite »
New breast cancer treatment not approved for NHS useThe health spending watchdog said the ‘the cost-effectiveness estimates were too high for it to be recommended for use in the NHS’.
Lire la suite »
The new face of local politics for the Conservatives as new chair is electedThere is a new chair of the Conservative group in Wigan
Lire la suite »